The genome e-volution (Volume 12)

“We have made great progress, but we are still vulnerable and our common commitment to fight global health challenges is not yet strong enough. Despite our knowledge, despite new technologies, without concentrated and global efforts we are limited in our success. Today we see it clearly.” The sequen...

Full description

Saved in:
Bibliographic Details
Format: Online
Language:English
Published: European Investment Bank 2021
Subjects:
Online Access:OCN: 1190760989
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1869518071052369920
collection Directory of Open Access Books
description “We have made great progress, but we are still vulnerable and our common commitment to fight global health challenges is not yet strong enough. Despite our knowledge, despite new technologies, without concentrated and global efforts we are limited in our success. Today we see it clearly.” The sequencing of the human genome at the beginning of this millennium marked a new era in biomedicine. Nanotechnology and robotics have created innovative tools and powerful diagnostic techniques. Major therapeutic advances have enabled us to control HIV, and more tailor-made therapies are being implemented to treat cancer. Nonetheless huge challenges remain, not only in the field of cancer, but also with respect to neurodegenerative and other diseases. At the same time, international travel and mobility, as well as globalised trade, are affecting our living conditions and promoting the spread of infectious diseases and new viruses, like the COVID-19 coronavirus, all over the world. The Croatian physician and scientist Ivan Đikić analyses the challenges of contemporary medical research, the emerging threats, like pandemics, and the role played by health systems. This is the twelfth essay in the Big Ideas series created by the European Investment Bank.
format Online
id doab-20.500.12854ir-64175
institution Directory of Open Access Books
language eng
publishDate 2021
publishDateRange 2021
publishDateSort 2021
publisher European Investment Bank
publisherStr European Investment Bank
record_format ojs
spelling doab-20.500.12854ir-641752025-07-31T17:54:46Z The genome e-volution (Volume 12) European Investment Bank Business & Economics Finance thema EDItEUR::K Economics, Finance, Business and Management::KF Finance and accounting::KFF Finance and the finance industry “We have made great progress, but we are still vulnerable and our common commitment to fight global health challenges is not yet strong enough. Despite our knowledge, despite new technologies, without concentrated and global efforts we are limited in our success. Today we see it clearly.” The sequencing of the human genome at the beginning of this millennium marked a new era in biomedicine. Nanotechnology and robotics have created innovative tools and powerful diagnostic techniques. Major therapeutic advances have enabled us to control HIV, and more tailor-made therapies are being implemented to treat cancer. Nonetheless huge challenges remain, not only in the field of cancer, but also with respect to neurodegenerative and other diseases. At the same time, international travel and mobility, as well as globalised trade, are affecting our living conditions and promoting the spread of infectious diseases and new viruses, like the COVID-19 coronavirus, all over the world. The Croatian physician and scientist Ivan Đikić analyses the challenges of contemporary medical research, the emerging threats, like pandemics, and the role played by health systems. This is the twelfth essay in the Big Ideas series created by the European Investment Bank. 2021-02-10T12:58:18Z 2021-03-20T04:32:11Z 2020 book OCN: 1190760989 https://library.oapen.org/handle/20.500.12657/47428 9789286146732 https://directory.doabooks.org/handle/20.500.12854/64175 eng open access image/png image/jpeg image/jpeg image/jpeg image/jpeg image/jpeg Attribution-NonCommercial-NoDerivatives 4.0 International Attribution-NonCommercial-NoDerivatives 4.0 International Attribution-NonCommercial-NoDerivatives 4.0 International Attribution-NonCommercial-NoDerivatives 4.0 International Attribution-NonCommercial-NoDerivatives 4.0 International Attribution-NonCommercial-NoDerivatives 4.0 International https://library.oapen.org/bitstream/20.500.12657/47428/1/QH0320217ENN.en.pdf https://library.oapen.org/bitstream/20.500.12657/47428/1/QH0320217ENN.en.pdf https://library.oapen.org/bitstream/20.500.12657/47428/1/QH0320217ENN.en.pdf https://library.oapen.org/bitstream/20.500.12657/47428/1/QH0320217ENN.en.pdf https://library.oapen.org/bitstream/20.500.12657/47428/1/QH0320217ENN.en.pdf https://library.oapen.org/bitstream/20.500.12657/47428/1/QH0320217ENN.en.pdf European Investment Bank European Investment Bank https://doi.org/10.2867/7 https://doi.org/10.2867/7 feca012f-a3d8-4aac-95aa-b6cf4bdbed7c Knowledge Unlatched 9789286146732 Knowledge Unlatched (KU) KU Open Services European Investment Bank open access
spellingShingle Business & Economics
Finance
thema EDItEUR::K Economics, Finance, Business and Management::KF Finance and accounting::KFF Finance and the finance industry
The genome e-volution (Volume 12)
title The genome e-volution (Volume 12)
title_full The genome e-volution (Volume 12)
title_fullStr The genome e-volution (Volume 12)
title_full_unstemmed The genome e-volution (Volume 12)
title_short The genome e-volution (Volume 12)
title_sort genome e volution volume 12
topic Business & Economics
Finance
thema EDItEUR::K Economics, Finance, Business and Management::KF Finance and accounting::KFF Finance and the finance industry
topic_facet Business & Economics
Finance
thema EDItEUR::K Economics, Finance, Business and Management::KF Finance and accounting::KFF Finance and the finance industry
url OCN: 1190760989